Testing Experimental Medication in Healthy Subjects

Eligibility Details: Inclusion Criteria: - Adult subjects 19 years of age or older, male or female - Female subjects must no longer have child-bearing potential (>1-year post menopause or surgically sterilized), or must - have a negative urine pregnancy test, and - be using and continue to use for 30 days after the study a medically effective method of contraception - Adequate hematologic, renal and hepatic function, as defined by: - Absolute neutrophil count (ANC) ≥ 1.5 x 109/L - Platelet count ≥ 100 x 109/L - Hemoglobin ≥ 90 g/L - Plasma creatinine< 1.5 x ULN - Total bilirubin within normal limits (< 2.5 x ULN if Gilbert's syndrome) - Aspartate transaminase (AST) and Alanine transaminase (ALT) < 2.5 x ULN - Subject must be willing and able to understand the study and provide written Informed Consent to participate in the study Exclusion Criteria: - Myocardial infarction within six months prior to enrollment - Unstable angina, NYHA Class II or greater congestive heart failure - EKG evidence of uncontrolled arrhythmia or history of clinically significant arrhythmia within the past six months - Clinically significant Chronic Obstructive Pulmonary Disease (COPD) or other pulmonary condition that is not controlled by medication or requires oxygen frequently or continuously - A history of pulmonary emboli - Known hypersensitivity to perflutren, DEFINITY® or other echo contrast agent - Inability to remain supine for 60 minutes - Oxygen saturation < 95% on room air - History of allergic reaction attributed to compounds of similar chemical composition to MVT-100 or DEFINITY® or soy or egg allergies (see Investigator's Brochure) - Subject has received any investigational drug within thirty (30) days prior to enrollment into the study - Inability to comply with study procedures - Subjects with any medical condition deemed by the investigator to make the subject inappropriate for participation